Avanos Medical Schedules Shareholder Vote for $25.00/Share Acquisition
AVNS has more than doubled off its 52-week low of $9.303.
Summary
Avanos Medical filed a definitive proxy statement for its special shareholder meeting on July 22, 2026, seeking approval for its acquisition by American Industrial Partners for $25.00 per share in cash.
Key Events · M&A and Partnerships · AVNS
-
Shareholder Meeting Scheduled
A special meeting of stockholders is scheduled for July 22, 2026, to vote on the proposed merger agreement.
-
Merger Terms Confirmed
Shareholders will receive $25.00 per share in cash upon completion of the merger, representing a 72.1% premium over the closing price on April 13, 2026, the day before the public announcement.
-
Board Unanimously Recommends Merger
The Board of Directors unanimously recommends that shareholders vote 'FOR' the Merger Proposal, the Advisory Compensation Proposal, and the Adjournment Proposal.
-
Financing Secured
Parent has obtained fully committed equity financing of $1.4 billion from American Industrial Partners Capital Fund VIII, L.P., with no financing condition for the merger.
Analysis · AVNS · Industrial Applications And Services
This definitive proxy statement is a critical procedural step towards the completion of Avanos Medical's acquisition by American Industrial Partners. The filing outlines the terms of the $25.00 per share all-cash offer, which represents a significant premium for shareholders. The Board's unanimous recommendation and the secured financing indicate a high likelihood of the merger closing, pending shareholder approval and the remaining regulatory clearance from Mexico.
At the time of this filing, AVNS was trading at $24.98 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.30 to $25.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.